Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: A pilot study with whole-blood aggregometry

American Heart Journal

Volumn 145, Issue 2, 2003, Pages 343-348

  Bauriedel, Gerhard ^a   Skowasch, Dirk ^a   Schneider, Melanie ^a   Andrié, René ^a   Jabs, Alexander ^a   Lüderitz, Berndt ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CLOPIDOGREL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; NITRATE; RAMIPRIL; STATIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ELECTRODE; FEMALE; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION;

EID: 0037323561     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.22     Document Type: Article

References (24)

1. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood 1994;83:885-98.
2. Brass S. Small cells, big issues. Nature 2001;409:145-7.
3. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-72.
4. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
5. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
6. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
7. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
8. O'Keefe JH, Wetzel M, Moe RR, et al. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol 2002;37:1-8.
9. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
10. Elwood PC, Beswick AD, Yarnell JWG, et al. Whole blood impedance platelet aggregometry and ischemic heart disease: the Caerphilly Collaborative Heart Disease Study. Arteriosclerosis 1990;10:1032-6.
11. Chirkov YY, Holmes AS, Willoughby SR, et al. Stable angina and acute coronary syndromes are associated with nitric oxide resistence in platelets. Am J Coll Cardiol 2001;37:1851-7.
12. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J 1998;135:170-8.
13. James IM, Dickenson EJ, Burgoyne W, et al. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens 1988;2:21-5.
14. Someya N, Morotomi Y, Kodama K, et al. Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 1984;6:840-3.
15. Zurbano MJ, Anguera I, Heras M, et al. Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIIa in early postmyocardial infarction stage. Arterioscler Thromb Vasc Biol 1999;19:1791-5.
16. Nishimura H, Tsuji H, Masuda, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator of tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997;77:1189-95.
17. Napoleone E, Di Santo A, Camera M, et al. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000;86:139-43.
18. Soejima H, Ogawa H, Yasue H. Effects of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction. Am J Cardiol 1996;78:336-40.
19. Francis GS. ACE inhibition in cardiovascular disease. N Engl J Med 2000;342:201-2.
20. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 2000;102:1748-54.
21. Pitt B. Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis. Am Heart J 1994;128:1328-32.
22. Fuster V. Mechanisms of arterial thrombosis: foundation for therapy. Am Heart J 1998;135:S361-6.
23. Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989;14:813-36.
24. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril. Circulation 1998;98:757-65.